Serina <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts $4.6 million net loss for third quarter 2025
Serina Therapeutics Inc. reported operating expenses of $6.4 million for the third quarter ended September 30, 2025, up from $5.3 million in the same period of 2024. General and administrative expenses were $2.7 million, compared to $2.9 million in the prior year, mainly due to reduced compensation costs partially offset by increased investor outreach expenses. Other income was $1.8 million, down from $6.7 million last year, primarily due to changes in the fair value of liability classified warrants, partially offset by gains from warrant expirations. The company reported a net loss of $4.6 million, or $0.45 per basic and diluted share, compared to net income of $1.4 million, or $0.16 per basic share and $0.13 per diluted share, in 2024. During the quarter, Serina launched a new corporate communications platform and continued its at-the-market equity program, issuing 474,712 shares at an average price of $6.00, raising $2.8 million in net proceeds. The company also highlighted FDA alignment on the advancement of its lead drug candidate, SER-252, under the 505(b)(2) NDA pathway.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-25-000135), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.